ECSP22016180A - Proteínas de fusión terapéuticas - Google Patents
Proteínas de fusión terapéuticasInfo
- Publication number
- ECSP22016180A ECSP22016180A ECSENADI202216180A ECDI202216180A ECSP22016180A EC SP22016180 A ECSP22016180 A EC SP22016180A EC SENADI202216180 A ECSENADI202216180 A EC SENADI202216180A EC DI202216180 A ECDI202216180 A EC DI202216180A EC SP22016180 A ECSP22016180 A EC SP22016180A
- Authority
- EC
- Ecuador
- Prior art keywords
- fusion proteins
- acute
- therapeutic fusion
- organ
- tissue
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/025—Services making use of location information using location based information parameters
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/029—Location-based management or tracking services
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Cell Biology (AREA)
- Signal Processing (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a proteínas de fusión adecuadas para su uso como medicamento o herramienta de investigación. Los usos terapéuticos de las proteínas de fusión pueden incluir la prevención o el tratamiento de trastornos inflamatorios agudos o crónicos y microvasculares y de órganos impulsados por el sistema inmunitario, por ejemplo, lesión renal aguda, síndrome de dificultad respiratoria aguda, sepsis, infarto agudo de miocardio, fibrosis tisular y otras lesiones de órganos resultantes del trauma tisular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196045 | 2019-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22016180A true ECSP22016180A (es) | 2022-04-29 |
Family
ID=67875416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202216180A ECSP22016180A (es) | 2019-09-06 | 2022-03-03 | Proteínas de fusión terapéuticas |
| ECSENADI202216558A ECSP22016558A (es) | 2019-09-06 | 2022-03-04 | Proteínas de fusión terapéuticas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202216558A ECSP22016558A (es) | 2019-09-06 | 2022-03-04 | Proteínas de fusión terapéuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20230308835A1 (es) |
| EP (3) | EP4025237A1 (es) |
| JP (3) | JP2022547050A (es) |
| KR (3) | KR20220058588A (es) |
| CN (3) | CN114302896A (es) |
| AR (2) | AR119902A1 (es) |
| AU (3) | AU2020343926A1 (es) |
| BR (2) | BR112022003762A2 (es) |
| CA (3) | CA3152499A1 (es) |
| CO (2) | CO2022002567A2 (es) |
| CR (2) | CR20220096A (es) |
| CU (2) | CU20220016A7 (es) |
| EC (2) | ECSP22016180A (es) |
| IL (3) | IL290618A (es) |
| JO (2) | JOP20220058A1 (es) |
| MX (2) | MX2022002638A (es) |
| PE (2) | PE20221051A1 (es) |
| TW (2) | TW202122414A (es) |
| WO (3) | WO2021044360A1 (es) |
| ZA (2) | ZA202201827B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020084344A2 (en) * | 2018-10-25 | 2020-04-30 | Nexel Co., Ltd. | Compositions and methods for treating or preventing fibrosis |
| EP4326307A1 (en) * | 2021-04-22 | 2024-02-28 | Biolegend, Inc. | Phosphatidylserine binding agents for the detection and depletion of phosphatidylserine positive cells |
| CN114288386B (zh) * | 2022-01-25 | 2023-12-12 | 华中科技大学同济医学院附属协和医院 | Del-1作为炎症性肠病新的生物标志物及治疗药物应用 |
| WO2024080854A1 (en) * | 2022-10-14 | 2024-04-18 | Illimis Therapeutics, Inc. | Fusion molecule and method for treating immunological diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| CA2405701A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2608271C (en) | 2005-05-13 | 2016-01-19 | The Feinstein Institute For Medical Research | Milk fat globule epidermal growth factor-factor viii and sepsis |
| CN101511866A (zh) * | 2006-09-08 | 2009-08-19 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| CN101910411B (zh) | 2007-11-15 | 2015-04-29 | 范斯坦医药研究院 | 使用mfg-e8预防和治疗缺血/再灌注后的炎症和器官损伤 |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| EP2536756B1 (en) | 2010-02-16 | 2018-04-25 | MedImmune, LLC | Hsa-related compositions and methods of use |
| CN106977608A (zh) | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| WO2012112188A1 (en) | 2011-02-15 | 2012-08-23 | Medimmune, Llc | Hsa-related compositions and methods of use |
| AU2012249539A1 (en) * | 2011-04-28 | 2013-11-14 | The Feinstein Institute For Medical Research | MFG-E8 and uses thereof |
| JP6430828B2 (ja) | 2011-05-05 | 2018-11-28 | アルブミディクス リミティド | アルブミン変異体 |
| US20140302027A1 (en) * | 2011-09-26 | 2014-10-09 | University Of Louisville Research Foundation, Inc. | Methods of treating periodontal inflammation and periodontal bone loss |
| GB2512156A (en) | 2012-11-08 | 2014-09-24 | Novozymes Biopharma Dk As | Albumin variants |
| EP2956002B1 (en) | 2013-02-16 | 2017-09-06 | Albumedix A/S | Pharmacokinetic animal model |
| WO2015025959A1 (ja) | 2013-08-23 | 2015-02-26 | 独立行政法人理化学研究所 | 蛍光特性を示すポリペプチド、およびその利用 |
| EP3127314B1 (en) * | 2014-03-31 | 2018-03-14 | British Telecommunications public limited company | Data communication |
| AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
| WO2015175512A1 (en) * | 2014-05-15 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of regulating bone resorption |
| KR20170013621A (ko) | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물 |
| WO2018158719A1 (en) * | 2017-03-02 | 2018-09-07 | Novartis Ag | Engineered heterodimeric proteins |
| US11028139B2 (en) | 2017-05-17 | 2021-06-08 | Nexel Co., Ltd. | Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same |
| WO2020084344A2 (en) | 2018-10-25 | 2020-04-30 | Nexel Co., Ltd. | Compositions and methods for treating or preventing fibrosis |
-
2020
- 2020-09-04 JP JP2022514568A patent/JP2022547050A/ja active Pending
- 2020-09-04 WO PCT/IB2020/058250 patent/WO2021044360A1/en active Application Filing
- 2020-09-04 WO PCT/IB2020/058251 patent/WO2021044361A1/en active Application Filing
- 2020-09-04 JP JP2022514843A patent/JP2022547111A/ja active Pending
- 2020-09-04 US US17/640,291 patent/US20230308835A1/en active Pending
- 2020-09-04 JO JOP/2022/0058A patent/JOP20220058A1/ar unknown
- 2020-09-04 CU CU2022000016A patent/CU20220016A7/es unknown
- 2020-09-04 US US17/640,295 patent/US20230220048A1/en active Pending
- 2020-09-04 TW TW109130528A patent/TW202122414A/zh unknown
- 2020-09-04 CN CN202080061631.8A patent/CN114302896A/zh active Pending
- 2020-09-04 AR ARP200102479A patent/AR119902A1/es unknown
- 2020-09-04 CN CN202080061624.8A patent/CN114341195A/zh active Pending
- 2020-09-04 MX MX2022002638A patent/MX2022002638A/es unknown
- 2020-09-04 CA CA3152499A patent/CA3152499A1/en active Pending
- 2020-09-04 KR KR1020227010907A patent/KR20220058588A/ko unknown
- 2020-09-04 AU AU2020343926A patent/AU2020343926A1/en active Pending
- 2020-09-04 MX MX2022002637A patent/MX2022002637A/es unknown
- 2020-09-04 US US17/640,293 patent/US20230265160A1/en active Pending
- 2020-09-04 EP EP20768408.5A patent/EP4025237A1/en active Pending
- 2020-09-04 AR ARP200102483A patent/AR119905A1/es unknown
- 2020-09-04 CA CA3152500A patent/CA3152500A1/en active Pending
- 2020-09-04 JP JP2022514570A patent/JP2022547051A/ja active Pending
- 2020-09-04 CR CR20220096A patent/CR20220096A/es unknown
- 2020-09-04 EP EP20768410.1A patent/EP4025239A1/en active Pending
- 2020-09-04 CN CN202080061452.4A patent/CN114341194A/zh active Pending
- 2020-09-04 KR KR1020227010891A patent/KR20220058585A/ko unknown
- 2020-09-04 BR BR112022003762A patent/BR112022003762A2/pt unknown
- 2020-09-04 EP EP20768409.3A patent/EP4025238A1/en active Pending
- 2020-09-04 BR BR112022003745A patent/BR112022003745A2/pt unknown
- 2020-09-04 JO JOP/2022/0055A patent/JOP20220055A1/ar unknown
- 2020-09-04 AU AU2020343512A patent/AU2020343512A1/en active Pending
- 2020-09-04 WO PCT/IB2020/058252 patent/WO2021044362A1/en unknown
- 2020-09-04 KR KR1020227010892A patent/KR20220058586A/ko unknown
- 2020-09-04 PE PE2022000372A patent/PE20221051A1/es unknown
- 2020-09-04 CU CU2022000015A patent/CU20220015A7/es unknown
- 2020-09-04 PE PE2022000365A patent/PE20220401A1/es unknown
- 2020-09-04 CR CR20220089A patent/CR20220089A/es unknown
- 2020-09-04 CA CA3152990A patent/CA3152990A1/en active Pending
- 2020-09-04 AU AU2020340618A patent/AU2020340618A1/en active Pending
- 2020-09-07 TW TW109130667A patent/TW202122415A/zh unknown
-
2022
- 2022-02-11 ZA ZA2022/01827A patent/ZA202201827B/en unknown
- 2022-02-11 ZA ZA2022/01828A patent/ZA202201828B/en unknown
- 2022-02-14 IL IL290618A patent/IL290618A/en unknown
- 2022-02-16 IL IL290660A patent/IL290660A/en unknown
- 2022-02-16 IL IL290675A patent/IL290675A/en unknown
- 2022-03-03 CO CONC2022/0002567A patent/CO2022002567A2/es unknown
- 2022-03-03 EC ECSENADI202216180A patent/ECSP22016180A/es unknown
- 2022-03-03 CO CONC2022/0002545A patent/CO2022002545A2/es unknown
- 2022-03-04 EC ECSENADI202216558A patent/ECSP22016558A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22016180A (es) | Proteínas de fusión terapéuticas | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| UY37182A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP109889A (es) | Composiciones terapeuticas y usos de las mismas | |
| MD3500241T2 (ro) | Terapie combinată pentru BPOC | |
| CY1124922T1 (el) | Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CL2017000117A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila. | |
| CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| BR112018068960A2 (pt) | formulações de enalapril | |
| CU20210008A7 (es) | Aspirasas solubilizadas | |
| EA201990947A1 (ru) | Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение | |
| CL2019002145A1 (es) | Composición farmacéutica que comprende betahistina. | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| EA201792170A1 (ru) | Производные индола | |
| ES2537905B2 (es) | Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales | |
| CL2017003465A1 (es) | Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria. |